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Abstract
Purpose: The aim of this study was to investigate the efficacy and safety of microwave ablation (MWA) in small hepa-
tocellular carcinomas sized ≤ 3 cm, determine long-term survival, and identify prognostic factors for survival rates.
Material and methods: In this study, the radiological and laboratory findings obtained from 31 consecutive patients 
who underwent MWA were retrospectively evaluated. The survival periods and complication rates were analysed.
Results: Microwave ablation was applied to 42 hepatocellular carcinoma nodules in 31 patients. The mean age of 
the patients was 61 ± 7.3 (median 62, range 46-78) years. The mean overall survival (OS) was 47.4 ± 3.3 months.  
The rates of cumulative OS in the first, second, and third years were 95.2%, 91.8%, and 79.2%, respectively. The mean 
disease-free survival (DFS) rate was 24.1 ± 2.5 months. The cumulative DFS rates in the first, second, and third years 
were 75.6%, 52.5%, and 28.2%, respectively. The number of tumours and tumour distribution were determined as 
prognostic factors. No major complication was detected, but six patients (13.9%) developed minor complications 
after MWA.
Conclusions: Microwave ablation in patients with hepatocellular carcinoma is a safety treatment modality with very 
low rates of complications. It offers an effective treatment with a high rate of complete response and local disease 
control according to the short-term results. In the long term, it prolongs the survival time of the treated patients. 
The number of tumours and tumour distribution were determined as prognostic factors affecting survival rates.
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Introduction
Hepatocellular carcinoma (HCC) is the most common 
primary malignant tumour of the liver, causing more 
than 800,000 deaths every year [1]. In the past, HCC was 
known to be a fatal disease with a poor prognosis because 
it was mostly detected in advanced stages. However, this 
situation has changed in recent years through screening 
and monitoring programs. Today, 30-60% of HCCs de-
tected in developed countries are at an early stage. Surgi-
cal treatment methods and ablation therapy can provide 
cure in patients with early stage HCCs, and a survival 
time reaching more than five years can be achieved [2-4].
In early stage HCCs, ablation methods have come 
to the forefront and started to be frequently used due to 
their significant advantages, including their less invasive 
and reproducible nature compared to surgical treatment 
methods. Radiofrequency ablation (RFA) is a relatively 
older method of ablation and has been used for many 
years in patients with early stage HCCs [5].
Microwave ablation (MWA) is a relatively new method 
of ablation. It provides more homogenous, higher tem-
peratures within the tumour in a shorter time compared 
to RFA. In addition, it theoretically offers more effective 
ablation in tumours adjacent to large vessels because it is 
less affected by the heat shrink effect [6]. There are stud-
ies in the literature suggesting that MWA can be used as 
an effective and safe treatment modality in patients with 
HCCs, but studies reporting the results of MWA treat-
ment in small HCCs (≤ 3 cm) are limited [2-7].
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The aim of this study was to investigate the efficacy 
and safety of MWA procedures for small HCCs (≤ 3 cm), 
determine the long-term survival, and identify prognostic 
factors for patients’ suvival after the MWA treatment.
Material and methods
This study was planned as a single-centre, retrospective 
study and conducted in accordance with the principles 
of the Helsinki Declaration after obtaining the approval 
of the local clinical research Ethics Committee (Number: 
0210201882/14). In this study, 31 consecutive patients 
who underwent the MWA procedure in the interventional 
radiology unit between March 2013 and November 2018 
were evaluated.
Patient population
The diagnosis was made according to the guidelines of 
the European Association for the Study of the Liver [8]. 
Patients with a tumour size of 3 cm or less and preserved 
liver function (Child-Pugh class A or B), for whom surgi-
cal treatment was not indicated because of comorbidity 
status, were considered to be appropriate for MWA treat-
ment and included in the study. Patients with refractory 
ascites, those with a bleeding disorder (indicated by an in-
ternational normalised ratio of > 1.5 and/or platelet value 
below 50,000/mm3), and those with tumour thrombus, 
who were not considered appropriate for MWA treatment, 
were excluded from the study.
Microwave ablation procedure
Informed consent was obtained from all patients before 
treatment. The patients were evaluated using ultrasound 
(US) for tumour location and size, adjacent structures, 
appropriate site for antenna entry, and tract. All abla-
tion procedures were percutaneously performed using 
a 3.5-5 MHz convex probe under the guidance of a US 
device (GE Logiq 7, GE Healthcare, WI) after inducing 
sedoanalgesia in patients (intravenous propofol [Corden 
Pharma SPA, Italy] and fentanyl [Yichang Renfu Pharma-
ceuticals, Huibei, China]).
For the MWA procedure, the Emprint MWA system 
(Covidien Boulder, CO) capable of generating 100 W en-
ergy at 2450 MHz or the AveCure MWA system (Med-
waves, CA) capable of generating 75 W energy at 915 MHz 
was used. As microwave antennas, 14 G internally cooled 
trocar-type percutaneous antennas were used. The ablation 
zone was determined to cover the entire tumour and 1 cm 
of the non-tumoral parenchyma as much as possible. When 
the appropriate ablation zone was obtained, the tract ablation 
was performed before the removal of the antenna to prevent 
tumour seeding and bleeding due to major vessel damage.
After MWA, the patients were kept under observation 
for 24 hours, and those with severe pain were adminis-
tered an intravenous injection of 100 mg Contramal, and 
those with mild pain were given intravenous 50 mg/2 ml 
dexketoprofen for analgesia. In addition, a single pro-
phylactic dose of 500 mg cefazolin was administered in-
tramuscularly. The next day, the patients were evaluated 
using physical examination and US, and after confirming 
that they did not have any major complication they were 
discharged from the hospital.
Follow-up and evaluation 
The patients were followed-up by laboratory tests and 
MRI at the first month after treatment, and then every 
third consecutive month. Liver functions and tumour 
markers were checked in laboratory tests. Contrast dy-
namic imaging was performed with a 1.5-Tesla Signa (GE 
Medical Systems, WI) or 3-Tesla Philips Achieva scanner 
(Phillips Medical Systems, The Netherlands) to evaluate 
treatment efficacy and recurrence.
Treatment efficacy was determined using the terminol-
ogy recommended in the Tumour Ablation Manual [9]. 
At the first-month follow-up, the absence of contrast en-
hancement within the tumour was evaluated as a com-
plete response, and partial enhancement as a partial re-
sponse. The ablation procedure was repeated in patients 
with a partial response. After observing a complete re-
sponse, the detection of contrast enhancement in the pa-
renchyma in the ablation zone or its vicinity during the 
follow-up was accepted as local recurrence. Newly devel-
oped tumours in the liver parenchyma but far from the 
ablation zone were considered intra-hepatic recurrence.
Complications were classified according to the guide-
lines of the Society of Interventional Radiology Clinical 
Practice Guidelines [10].
Statistical analysis
In the descriptive statistics, continuous variables were ex-
pressed as mean and standard deviation values, and categor-
ical variables as numbers and percentages. The survival time 
was analysed by the Kaplan-Meier method, and the effects 
of categorical variables on survival were evaluated using the 
log-rank test. The c2 and Fisher’s exact c2 tests were used to 
determine whether there was a statistical difference between 
categorical variables. In all statistical tests, p values  less than 
0.05 were considered statistically significant. For the statisti-
cal analysis of the data, TURCOSA software (Turcosa Ana-
lytical Ltd., Turkey) was used.
Results
In this study, the MWA treatment response and compli-
cation rates of 31 patients with 42 HCC nodules were 
evaluated. The demographic and clinical characteristics 
of the patients are summarised in Table 1. Additionally, 
Eastern Cooperative Oncology Group performance scale 
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score ranged from 0 to 2 for all patients. Before treat-
ment, mild ascites (3.2%), severe hypoalbuminaemia 
(< 2.8 g/dl) (3.2%), and severe bilirubin elevation (> 3 g/dl) 
(3.2%) were detected in one patient each. Table 2 sum-
marises the characteristics of the treated tumours at the 
time of diagnosis. Briefly, the mean size of MWA-treated 
tumours was 1.92 ± 0.4 cm (median 1.9, range 1.3-3.0 cm).
In this study, technical success was achieved in all 
MWA-treated cases, and the mean ablation time was cal-
culated as 5.6 ± 2.6 min (median 5, range 2-15 min). Mor-
tality and major complications did not occur after MWA. 
Six patients (14.3%) developed minor complications after 
MWA: pleural effusion (4/6), biliary dilatation (1/6), and 
subcapsular haematoma (1/6). All minor complications 
were spontaneously resolved during the follow-up without 
treatment.
The mean follow-up period after MWA was 31.5 ± 
14.4 months (median 29, range 8-66 months). During the 
follow-up, 11 (35.4%) patients died, and one patient (3.2%) 
was excluded from further analysis due to undergoing liver 
transplantation. In the first-month radiological evalua-
tion of MWA-treated tumours, 41 tumours (97.6%) had 
a complete response and one (2.4%) had a partial response 
(Figures 1 A-D). During the follow-up, local recurrence 
occurred in three tumours (7.1%) and intra-hepatic recur-
rence was observed in 21 (50%). In addition, colon metas-
tasis was detected in one case (2.4%) and lung metastasis 
in two cases (4.8%).
When the Kaplan-Meier survival analysis was per-
formed, the mean overall survival (OS) time was calcu-
lated as 47.4 ± 3.3 months (Figure 2). The cumulative 
OS rates in the first, second, and third years was 95.2%, 
91.8%, and 79.2%, respectively. When the effects of clini-
cal and tumour characteristics on survival were examined, 
the number of tumours and tumour distribution in the 
liver were determined as prognostic factors. The OS time 
was significantly higher in patients with a single tumour 
compared to those with 2-3 tumours (50.3 ± 1.8 vs. 39.4 
± 3.8 months, respectively; p = 0.018), and it was also 
significantly higher in patients with bilobar distribution 
compared to those with unilobar tumours (48.9 ± 2.2 vs. 
39 ± 4.3 months, p = 0.029) (Figures 3 and 4). The base-
line α-fetoprotein (AFP) value, Child-Pugh score, and 
hepatitis aetiology did not have a significant effect on the 
survival time of patients who underwent MWA (p = 0.614, 
p = 0.999, and p = 0.669, respectively) (Table 3).
The Kaplan-Meier survival analysis revealed the mean 
disease-free survival (DFS) as 24.1 ± 2.5 months (Figure 5). 
The cumulative DFS rates in the first, second, and third 
years were 75.6%, 52.5%, and 28.2%, respectively. The pa-
tients with a single tumour had significantly higher DFS 
time than those with 2-3 tumours (33.2 ± 2.6 vs. 16.5 ± 2.4 
months, respectively; p = 0.0002), and the patients with uni-
lobar tumour distribution had a significantly higher DFS 
time than those with bilobar tumours (27.2 ± 2.7 vs. 17.4 ± 
3.2 months, respectively; p = 0.029) (Figures 6 and 7).
Discussion
Hepatocellular carcinoma is the most common primary 
malignant tumour of the liver and the fifth most common 
cancer. Ablation treatment has become one of the first 
treatment options for tumours of ≤ 3 cm in size because 
this method is less invasive and more reproducible com-
pared to surgical procedures [11].
The incidence of HCC was found to be two to three 
times higher in the male population than in females [12]. 
Similarly, in our study, the male patients constituted the 
majority (83.9%), and the male/female ratio was even 
higher than reported in the literature. This is because the 
male/female ratio of viral hepatitis is higher in Turkey 
compared to other countries [13]. Because HBV infection 
is endemic in Turkey, the incidence of HBV was higher 
in our sample with HCCs compared to the literature; 
the causative agent was detected as HBV in 24 patients 
(77.4%) and HCV in seven (22.6%) [14].
With the development of MWA technology used in 
HCC patients over the years, positive results have been 
Table 1. Demographic and clinical characteristics of the patients
Variable Results







Hepatitis aetiology, n (%)
Hepatitis B virus 24 (77.4)
Hepatitis C virus 7 (22.6)
Alpha-fetoprotein (ng/ml), n (%) 
≤ 20 23 (74.2)
> 20 8 (25.8)
SD – standard deviation.
Table 2. Characteristics of microwave ablation-treated tumours
Variable Results
Number of tumours, n (%)
1 17 (40.5)
2-3 25 (59.5)
Tumour distribution, n (%)
Unilobar 25 (59.5)
Bilobar 17 (40.5)
Tumour size (cm), mean ± SD 1.9 ± 0.4 
SD – standard deviation.
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Figure 1. A 61-year-old male patient was treated with microwave ablation after the detection of hepatocellular carcinoma in magnetic resonance imaging. 
A) On axial T1-weighted early arterial phase image, a hyperintense nodule lesion (diameter: 1.5 mm) was detected in segment five. B) On axial T1-weight-
ed venous phase, the lesion was washed out of contrast material. C, D) On the axial T1-weighted portal phase image, the lesion was complete ablate at 
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applied MWA to 46 HCC nodules of ≤ 3 cm and found 
a complete response in 41 (89.1%) [15]. More recently, in 
a 2014 study, Abdelaziz et al. achieved a complete response 
in 54 (98.2%) of 55 HCC nodules of ≤ 3 cm after MWA 
treatment [16]. Internally cooled antenna systems used 
in MWA systems have enabled the ablation energy to be 
distributed more homogenously within the tumour com-
pared to old antenna systems, thus resulting in higher ef-
ficacy in the outer parts of the tumour. Therefore, the rates 
of complete response rates have increased over the years. 
However, as tumour size increases (> 3 cm), the complete 
response rate and the early efficacy of MWA in local dis-
ease control is reduced due to insufficient energy distri-
bution within the tumour. Medhat et al. applied MWA to 
26 HCCs between 5 and 7 cm and achieved a complete 
response in 19 (73.1%) tumours [17]. Liu et al. calculated 
the complete response rates as 75% (21/28) for 5-8 cm tu-
mours and 94.2% (45/48) for 3-5 cm tumours. A signifi-
cant difference was detected in the complete response rates 
increasingly obtained in terms of local disease control and 
early outcome. First, in their study in 2002, Shibata et al. 
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Table 3. Effect of clinical and tumour characteristics on survival time
Variable (mean ± SD) Overall survival time (months) p-value Disease-free survival time (months) p-value
Number of tumours
1 50.3 ± 1.8 0.018 33.2 ± 2.6 0.0002
2-3 39.4 ± 3.8 16.5 ± 2.4
Tumour distribution
Unilobar 48.9 ± 2.2 0.029 27.2 ± 2.7 0.029
Bilobar 39 ± 4.3 17.4 ± 3.2
α-fetoprotein (ng/ml)
≤ 20 47.1 ± 3.1 0.614 23.3 ± 2.6 0.794
> 20 43.2 ± 6.4 24 ± 4.3
Hepatitis aetiology
Hepatitis B virus 46.6 ± 3.1 0.999 24 ± 2.5 0.459
Hepatitis C virus 47.2 ± 6.3 21.1 ± 4.5
Child-Pugh
A 47.2 ± 3.5 0.669 23 ± 2.3 0.807








Figure 4. Overall survival times of microwave ablation-treated hepatocel-




































Figure 3. Overall survival times of microwave ablation-treated hepatocellu-
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of these two groups with a different tumour size range 
(p = 0.033) [18]. All of the MWA antennas used in our 
study were internally cooled, and the mean size of HCC 
nodules was 1.9 ± 0.4 cm (median 1.9, range 1.3-3 cm). In 
the evaluation of early results, 41 (97.6%) of the tumours 
had a complete response, and one (2.4%) had a partial re-
sponse. Considering the data in the literature and the early 
results of our study, MWA presents as a very effective treat-
ment modality in terms of local disease control in HCCs 
of ≤ 3 cm. However, as the tumour size increases, the early 
success rate (complete response rate) decreases.
While the early results of MWA are positive in patients 
with HCCs, recurrences reaching 50% are detected in the 
long-term follow-up. Sun et al., who evaluated 182 pa-
tients who underwent MWA, achieved a 93% complete 
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Figure 6. Disease-free survival times of microwave ablation-treated hepato-
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response rate in the first-month evaluation, but during 
the later follow-up, 54.2% of the patients developed intra- 
hepatic recurrence [19]. In a study by Abdelaziz et al., 
local tumour recurrence was found as 3.9% and intra- 
hepatic recurrence as 13.6% [16]. In MWA-treated HCCs, 
Ding et al. detected the OS rates as 98%, 90.7%, and 77.6% 
for the first, second, and third years, respectively, and 
the DFS rates were 75%, 59.4%, and 32.1%, respectively. 
In addition, the mean OS time was 45.3 ± 2.2 months, 
and the mean DFS time was 25 ± 1.6 months [20]. In the 
current study, local tumour recurrence was detected in 
three tumours (7.1%) and intra-hepatic recurrence in 
21 (50%), and the OS and DFS times were calculated as 
47.4 ± 3.3 months and 24.1 ± 2.5 months, respectively, 
which is consistent with the long-term results of previous 
studies in the literature. The success rate of HCC treat-
ment in terms of OS time is low due to recurrence in the 
long term because these nodules frequently develop on 
the background of cirrhotic liver parenchyma. However, 
because MWA can be repeated multiple times even in pa-
tients with decreased liver parenchymal reserve, longer 
OS times can be obtained in early-stage tumours.
Since the group of HCC patients is heterogeneous and 
the disease has different treatment options with varying 
efficacy, studies have been conducted to identify prognos-
tic factors for appropriate treatment and patient selection 
and to examine their effects on survival. Xu et al. applied 
thermal ablation treatment (RFA and MWA) to 137 pa-
tients and evaluated 16 possible prognostic factors at the 
end of the four-year follow-up [21]. The serum AFP value 
and Child-Pugh score at the time of diagnosis were re-
ported to be predictive factors of prognosis. In an article 
published in 2017, Ma et al. treated 433 patients using 
MWA, and as a result, they identified the prognostic fac-
tors as the number of tumours, a tumour size of > 5 cm, 
and a high AFP value at the time of diagnosis [22]. In the 
present study, the number of tumours and tumour distri-
bution, aetiology of hepatitis, AFP values, and Child-Pugh 
score at diagnosis were evaluated as possible prognostic 
factors. The number of tumours and tumour distribution 
at the time of diagnosis were determined as prognostic 
factors affecting OS and DFS times. A tumour count of 
more than 1 and bilobar distribution of HCC nodules in 
the liver is a common disease marker. The risk of recur-
rence is higher in these patients. In this study, the AFP 
values and Child-Pugh score did not present as prognostic 
factors. In the literature, it was found that in patients with 
HCCs, the serum AFP values were increased in the ac-
tive disease state (necrosis and regeneration). Therefore, 
serum AFP values are important markers in terms of dis-
ease prognosis at the time of diagnosis and recurrence in 
follow-up [21]. Since the Child-Pugh score offers a clue 
to possible liver failure, it can be predicted that patients 
with high tumour-independent Child-Pugh score will 
have shorter survival times associated with liver failure.
In an article published to create a common report-
ing language in patients who underwent ablation, Ahmed 
et al. considered as major complications those that caused 
morbidity and required hospitalisation or additional treat-
ment. The authors included the remaining complications 
in the category of minor complications [9]. In a systematic 
meta-analysis by Bertot et al., studies conducted between 
1982 and 2010 were compiled and a total of 1185 MWA 
procedures were reviewed. The major complication rate 
was found as 4.6% and the mortality rate as 0.23% [23]. 
No vascular complications were observed in our study. 
This was achieved because the pre-procedural bleeding 
profiles of all patients were within the normal range and 
the needle tract was cauterised by ablation at the end of 
the procedure.
Minor complications are those that do not require 
additional treatment, such as subcapsular hematoma, 
perihepatic collection, skin burns, and ipsilateral pleural 
effusion [9]. These complications do not cause additional 
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morbidity as long as they are controlled. In this study, 
minor complications (pleural effusion, perihepatic col-
lection, and biliary dilatation) developed in six patients 
(14.2%) after MWA treatment.
Post-treatment fever and abdominal pain indicate post-
ablation syndrome and are defined as side effects. These side 
effects can be controlled by keeping the patient under ob-
servation for the first 24 hours and administering low-dose 
anti-inflammatory medication [9]. In this study, prophylac-
tic analgesia and anti-inflammatory treatment were applied 
to all patients; thus, possible side effects were prevented.
There were some limitations to our study. Due to the 
retrospective nature of the study, the appropriate sam-
ple size was not calculated before the study. In addition, 
the 5- and 10-year long-term results of patients who under-
went MWA were not available. Therefore, there was only 
limited information about the local recurrence of the pa-
tients in some periods.
Conclusion
MWA is a safe treatment modality in patients with 
HCCs because it has a very low risk of complications, 
and in the event of complications, appropriate and timely 
treatment completely restores the patients’ health. MWA 
is also an effective treatment modality in patients with 
HCCs considering that the short-term results indicate 
a high rate of complete response and local disease con-
trol, while the long-term results reveal prolonged survival 
time in MWA-treated patients. The number of tumours 
and tumour distribution were determined as prognostic 
factors affecting survival rates.
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